Literature DB >> 3881119

Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.

C Benedetto, M Zonca, A M Tavella, E Petitti, M Massobrio, S Nigam, T F Slater.   

Abstract

Platelet sensitivity to prostacyclin (PG12) was determined in normal male and female subjects, and in patients with benign and malignant tumours of the breast. The IC50 overall mean values for PG12 on ADP-induced platelet aggregation were similar for normal men and women, being 0.97 +/- 0.05 ng ml-1 and 0.83 +/- 0.07 ng ml-1 respectively. However, there were significant differences in the IC50 values for women in the 1st (0.81 +/- 0.06 ng ml-1) vs. 2nd (1.37 +/- 0.13 ng ml-1) phase of the menstrual cycle; post-menopausal women gave similar values to normal males and to pre-menopausal women in the 1st phase of the cycle. No significant differences were found between normal subjects and patients with benign or malignant tumours of the breast when account was taken of the status of the patient in relation to the phase of the menstrual cycle and the menopause. The importance of the hormonal status in evaluating changes in platelet sensitivity in patients with breast cancer is strongly emphasised.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881119      PMCID: PMC1976827          DOI: 10.1038/bjc.1985.7

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

1.  Breast cancer, its recurrence, and patient survival in relation to tumor prostaglandins.

Authors:  A Bennett; D A Berstock; M A Carroll; I F Stamford; A J Wilson
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1983

Review 2.  Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis.

Authors:  K V Honn; W D Busse; B F Sloane
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

3.  Prostaglandin I2 receptors in a particulate fraction of platelets of various species.

Authors:  E Schillinger; G Prior
Journal:  Biochem Pharmacol       Date:  1980-09-01       Impact factor: 5.858

Review 4.  The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications.

Authors:  S Bunting; S Moncada; J R Vane
Journal:  Br Med Bull       Date:  1983-07       Impact factor: 4.291

Review 5.  Pharmacological interactions between prostacyclin and thromboxanes.

Authors:  B J Whittle; S Moncada
Journal:  Br Med Bull       Date:  1983-07       Impact factor: 4.291

6.  Sensitivity of platelets to prostaglandins in cornary heart disease and angina pectoris.

Authors:  H Sinzinger; G Schernthaner; J Kaliman
Journal:  Prostaglandins       Date:  1981-11
  6 in total
  1 in total

Review 1.  Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract.

Authors:  S Nigam; A Zakrzewicz; S Eskafi; A Roscher
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.